Literature DB >> 2469708

Effect of cetirizine on mast cell-mediator release and cellular traffic during the cutaneous late-phase reaction.

E N Charlesworth1, A Kagey-Sobotka, P S Norman, L M Lichtenstein.   

Abstract

A new H1 antihistamine, cetirizine, was studied to determine its effects on mediators and cellular infiltration during the cutaneous late-phase response (LPR). Ten ragweed-allergic subjects, who had previously demonstrated a cutaneous LPR, were examined in a double-blind, crossover study. Either cetirizine, 20 mg, or placebo was administered orally once daily for 2 days before and the morning of placement of a skin chamber overlying an unroofed heat/suction-induced blister to which was added antigen or buffer. Skin test erythema was significantly reduced by cetirizine at 15 minutes, 2 hours, and 4 hours by 56%, 40%, and 39%, respectively (all, p less than or equal to 0.01), but by 6 and at 8 hours, the cutaneous erythema was not significantly lessened. Histamine release was not altered by cetirizine treatment, but prostaglandin D2 (PGD2) production, which peaked at 3 to 5 hours, was clearly reduced by cetirizine treatment, being lower at all time points during the reaction; this was significant by analysis of variance (p less than or equal to 0.04). The inhibition was most marked during the fifth hour of the reaction when there was a 50% suppression of the PGD2 level by cetirizine (0.193 ng/ml to 0.075 ng/ml [p less than or equal to 0.03]). The most dramatic effect of cetirizine was attenuation of the inflammatory cell migration into the chamber. Eosinophil infiltration was decreased by about 75% during hours 6, 7, and 8 (p less than or equal to 0.04), whereas the number of neutrophils was reduced by the same magnitude at the same times (p less than or equal to 0.04).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2469708     DOI: 10.1016/0091-6749(89)90104-8

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  21 in total

Review 1.  New insights into the second generation antihistamines.

Authors:  G M Walsh; L Annunziato; N Frossard; K Knol; S Levander; J M Nicolas; M Taglialatela; M D Tharp; J P Tillement; H Timmerman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Pharmacotherapy of childhood asthma. An inflammatory disease.

Authors:  H P Van Bever; W J Stevens
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

Review 3.  Allergic rhinitis.

Authors:  C J Trigg; R J Davies
Journal:  Arch Dis Child       Date:  1991-05       Impact factor: 3.791

4.  Suppression of histamine-induced skin reactions by loratadine and cetirizine diHCl.

Authors:  K Kontou-Fili; G Paleologos; M Herakleous
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 5.  Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy.

Authors:  F E Simons; K J Simons
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

6.  The effect of cetirizine on antigen-dependent leucopenia in the guinea-pig.

Authors:  A J Coyle; J Lefort; B B Vargaftig
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

7.  Interference of cetirizine with the late eosinophil accumulation induced by either PAF or compound 48/80.

Authors:  M A Martins; C P Pasquale; P M e Silva; A L Pires; C Ruffié; J P Rihoux; R S Cordeiro; B B Vargaftig
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

8.  Effect of cetirizine, ketotifen and chlorpheniramine on the dynamics of the cutaneous hypersensitivity reaction: a comparative study.

Authors:  J R Snyman; D K Sommers; M D Gregorowski; H Boraine
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

9.  Cetirizine: a review of its use in allergic disorders.

Authors:  Monique P Curran; Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis.

Authors:  Friedrich Horak
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.